



ASX Announcement

Thursday August 14, 2014

Contracts signed since 1 July 2014 hit \$9 million

MELBOURNE, AUSTRALIA: Cognition technology company Cogstate (CGS.ASX) is pleased to announce that it has secured a \$0.8 million sales contract for the provision of computerised cognition testing technology and associated services in a phase II study in Glioblastoma (brain tumour).

This contract takes the total value of clinical trial sales contracts signed since 1 July 2014 to over \$9.0 million.

At this time, Cogstate has sales contracts in place that will generate \$9.1 million of clinical trials revenue for the 2015 financial year, including \$1 million that was invoiced in July. At this time last year, Cogstate had secured \$6.5 million of revenue for the 2014 financial year.

Cogstate has total contracted future revenue of \$19.7 million, which be recognised over the course of the various studies (compared to \$9.8 million at the same time last year). At this time, the estimated timing of that revenue is as follows:

- FY2015 \$9.1 million
- FY2016 \$5.3 million
- FY2017 \$2.9 million
- FY2018 \$1.9 million
- Later periods \$0.6 million

Study Details

As part of the study, 230 will be tested at 65 sites in 12 countries. The study will run for 34 months, however the specifics of the study mean the a high proportion of the services provided by Cogstate will be delivered in the first 12 months, meaning that a large percentage of the total contract value will be recognised as revenue in the 2015 financial year.

For further information contact:

Brad O'Connor
Tel: +61 (0)411 888 347
Email: boconnor@cogstate.com

About Cogstate

Cogstate Ltd (ASX: CGS) is a multi-faceted cognitive assessment and training company, focused on the development and commercialisation of rapid, computerised tests of cognition (brain function). It has three distinct business units:

Clinical Trials: In the clinical drug trial market, Cogstate technology and associated services are used by pharmaceutical and biotechnology companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.

Concussion: In the area of sports related concussion, Cogstate's technology has been used by a number of highly regarded institutions and sporting organisations around the world for almost 10 years.

Healthcare: In the primary care or general practice setting, COGNIGRAM™ assesses cognition in patients and the reports generated on the basis of this assessment can allow physicians to identify subtle changes that could be indicative of the early stage of a neurodegenerative disease, such as Alzheimer's disease.